Intravenous Labetalol Versus Hydralazine in Preeclampsia

Last updated: November 26, 2024
Sponsor: Tanta University
Overall Status: Active - Recruiting

Phase

1/2

Condition

N/A

Treatment

Labetalol Injection

HydrALAZINE Injection

Clinical Study ID

NCT06360601
36264PR589/3/24
  • Ages 25-45
  • Female

Study Summary

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patient with clinical diagnosis of sever preeclampsia

Exclusion

Exclusion Criteria:

Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Labetalol Injection
Phase: 1/2
Study Start date:
April 01, 2024
Estimated Completion Date:
December 20, 2024

Connect with a study center

  • Faculty of Medicine

    Tanta, 3511
    Egypt

    Site Not Available

  • Tanta Univeristy hospitals

    Tanta,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.